Sanjay Kaul

Q: What Schools Are Affiliated With Sanjay Kaul

Sanjay Kaul is affiliated with the following schools: University of California, Los Angeles, Stanford University, Lund University

Sanjay Kaul's AcademicInfluence.com Rankings

Sanjay Kaul

Computer Science

#9001

World Rank

#9459

Historical Rank

Machine Learning

#3831

World Rank

#3877

Historical Rank

Artificial Intelligence

#4154

World Rank

#4212

Historical Rank

Database

#5995

World Rank

#6216

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Sanjay Kaul's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University

Similar Degrees You Can Earn

Why Is Sanjay Kaul Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sanjay Kaul's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium (2011) (3111)
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. (2003) (2963)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (2020) (1835)
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. (2003) (1200)
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. (2012) (672)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2008) (581)
Low diagnostic yield of elective coronary angiography. (2010) (546)
ACCF/AHA Expert Conseusus Document (2009) (530)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association (2010) (515)
Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. (1999) (502)
From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report (2006) (475)
ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. (1999) (431)
2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. (2017) (394)
High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization (2001) (391)
Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. (2000) (378)
Transcatheter aortic-valve replacement with a self-expanding prosthesis. (2014) (371)
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. (2012) (367)
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I (2001) (318)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum (2017) (314)
What the Tortoise said to Achilles. (2010) (314)
Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. (1999) (309)
Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. (1999) (301)
Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials (2006) (257)
From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. (2006) (251)
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death (2007) (250)
Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. (1998) (248)
Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function. (1995) (248)
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II (2001) (227)
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2008) (223)
Trial and Error (2007) (194)
The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. (2013) (191)
Trial and error. How to avoid commonly encountered limitations of published clinical trials. (2010) (188)
Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. (2008) (181)
Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two-dimensional echocardiography. (1989) (176)
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. (2013) (171)
Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis (2015) (168)
Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. (2006) (167)
Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. (1991) (161)
Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. (1999) (152)
The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors (2017) (144)
Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. (1999) (133)
The impact of revascularization on mortality in patients with nonacute coronary artery disease. (2009) (131)
Differential Effects of Apolipoprotein A-I–Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice (2004) (130)
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. (2010) (130)
Narrative Review: Drug-Eluting Stents for the Management of Restenosis: A Critical Appraisal of the Evidence (2006) (128)
Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. (1998) (126)
Non-inferiority study design: lessons to be learned from cardiovascular trials. (2012) (126)
Functional improvement precedes structural regression of atherosclerosis. (1994) (126)
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society (2012) (123)
Acute myocardial infarction in human immunodeficiency virus-infected patients. (2003) (119)
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. (2010) (117)
ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography (2010) (115)
Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. (1999) (112)
Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. (2004) (106)
Trials and tribulations of non-inferiority: the ximelagatran experience. (2005) (101)
Elevated Troponin I Level on Admission Is Associated With Adverse Outcome of Primary Angioplasty in Acute Myocardial Infarction (2000) (97)
Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials (2011) (91)
Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? (2000) (88)
Nuclear factor-κB activity and arterial response to balloon injury (1997) (86)
ACCF/AHA new insights into the methodology of performance measurement: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures. (2010) (81)
Cost, effectiveness, and cost-effectiveness. (2009) (79)
Intramural Delivery of Recombinant Apolipoprotein A-IMilano/Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries (2003) (76)
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Societ (2012) (76)
Fibrates in the treatment of dyslipidemias--time for a reassessment. (2011) (69)
Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. (2004) (68)
Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. (2000) (68)
ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3) (2015) (66)
By Jove! What is a clinician to make of JUPITER? (2010) (66)
Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. (1998) (65)
Hazardous to your health: kinetic foundations of risk stratification and therapeutic triage. (2006) (60)
Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. (2017) (60)
Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. (2000) (58)
COURAGE under fire: on the management of stable coronary disease. (2007) (57)
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial (2021) (56)
How would the Reverend Bayes interpret high-sensitivity troponin? (2010) (55)
The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven (2012) (55)
ACCF/AHA New Insights Into the Methodology of Performance Measurement: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (2010) (53)
As time goes by: current status and future directions in the controversy over stenting. (2007) (51)
Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. (2012) (50)
Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease (2007) (49)
Comparative Antithrombotic Effects of Magnesium Sulfate and the Platelet Glycoprotein IIb/IIIa Inhibitors Tirofiban and Eptifibatide in a Canine Model of Stent Thrombosis (2002) (49)
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials (2017) (48)
Evidence-based use of statins for primary prevention of cardiovascular disease. (2012) (47)
Efficacy of 0.2% tempered chlorhexidine as a pre-procedural mouth rinse: A clinical study (2012) (46)
Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. (1997) (43)
Effect of Exposure to Cigarette Smoke on Carotid Artery Intimal Thickening: The Role of Inducible NO Synthase (2004) (43)
Screen testing cardiovascular prevention in asymptomatic diabetic patients. (2007) (42)
2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement (2012) (42)
Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. (1997) (42)
Advances in antiplatelet treatment for acute coronary syndromes (2009) (42)
Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial (2019) (41)
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). (2013) (41)
Risk and the physics of clinical prediction. (2014) (41)
Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels. (1993) (38)
Patient Selection for Elective Revascularization to Reduce Myocardial Infarction and Mortality: New Lessons From Randomized Trials, Coronary Physiology, and Statistics (2015) (38)
Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations (2012) (37)
Troponin Testing for Clinicians. (2016) (37)
Statins in acute coronary syndromes: do the guideline recommendations match the evidence? (2009) (36)
Expert Consensus Document Accf/acr/aha/nasci/scmr 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Writing Committee Members Expert Consensus Document Table of Contents Hundley Et Al (2010) (36)
Intravenous Magnesium in Experimental Stent Thrombosis in Swine (2001) (35)
Nuclear factor-kappaB activity and arterial response to balloon injury. (1997) (35)
Altered vascular responses to platelets from hypercholesterolemic humans. (1993) (34)
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? (2010) (33)
Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. (2007) (33)
Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. (1996) (31)
In search of the vulnerable plaque: is there any light at the end of the catheter? (2014) (30)
The things to come of SHAPE: cost and effectiveness of cardiovascular prevention. (2007) (29)
The aggressive low density lipoprotein lowering controversy. (2000) (27)
Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. (2011) (24)
The Case For and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity. (2016) (24)
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True? (2016) (24)
Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. (2021) (23)
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline (2019) (23)
Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. (2002) (23)
Bayesian classification of clinical practice guidelines. (2009) (21)
COCATS 4 Task Force 11: Training in Arrhythmia Diagnosis and Management, Cardiac Pacing, and Electrophysiology. (2015) (21)
Evidence-based financial incentives for healthcare reform: putting it together. (2009) (21)
From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events. (2007) (20)
Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. (2000) (20)
Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals (2019) (19)
Effect of atherosclerosis on responses of the perfused rabbit carotid artery to human platelets. (1992) (18)
Differentiation of adherent human monocytes into macrophages markedly enhances tissue factor protein expression and procoagulant activity. (2002) (18)
Interaction of human platelets and leukocytes in modulation of vascular tone. (1994) (18)
Bridging therapy in the perioperative management of patients with drug-eluting stents. (2009) (18)
Phosphatase activity in the arterial wall after balloon injury: effect of somatostatin analog octreotide. (1999) (18)
Vascular responses to platelet activation in normal and atherosclerotic primates in vivo. (1991) (16)
A Prospective, Nonrandomized, Open-Labeled Pilot Study Investigating the Use of Magnesium in Patients Undergoing Nonacute Percutaneous Coronary Intervention with Stent Implantation (2003) (16)
Prevention and treatment: a tale of two strategies. (2008) (16)
Plasma Apolipoprotein B Levels Predict Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease (1998) (15)
The disconnect between practice guidelines and clinical practice--stressed out. (2008) (15)
2012 American college of cardiology foundation/society for cardiovascular angiography and interventions expert consensus document on cardiac catheterization laboratory standards update: American college of cardiology foundation task force on expert consensus documents society of thoracic surgeons so (2012) (15)
Diabetes: Breaking news! Rosiglitazone and cardiovascular risk (2010) (15)
Subgroup analyses in trial reports comparing percutaneous coronary intervention with coronary artery bypass surgery. (2013) (15)
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. (2019) (14)
Rosiglitazone and cardiovascular risk (2008) (14)
Cardiovascular risk assessment in the development of new drugs for obesity. (2012) (14)
Gone fishing!: on the "real-world" accuracy of computed tomographic coronary angiography: Comment on the "Ontario multidetector computed tomographic coronary angiography study". (2011) (14)
Cardiac amyloidosis: new insights into diagnosis and management. (2007) (14)
Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week. (2020) (13)
Primary angioplasty for acute myocardial infarction in octogenarians. (2001) (13)
Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance. (2010) (13)
Effects of GP IIb/IIIa Receptor Inhibitor Tirofiban (Aggrastat) in Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis (2003) (13)
Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: An alternative perspective. (2014) (12)
Correlation between left ventricular risk area and clinical, electrocardiographic, hemodynamic, and angiographic variables during acute myocardial infarction. (1990) (12)
Making the case for selective use of statins in the primary prevention setting. (2011) (11)
Periodontal Status amongst Substance Abusers in Indian Population (2012) (11)
Asymmetry of vascular responses of perfused rabbit carotid artery to intraluminal and abluminal vasoactive stimuli. (1992) (11)
Gangrene Complicating Dopamine Therapy (1997) (11)
Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes. (2015) (10)
ApoA-I Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression. (2005) (10)
The JUPITER Trial: Myth or Reality? (2011) (9)
Medical device regulatory reform: insights from the watchman left atrial appendage closure technology for stroke prophylaxis in atrial fibrillation. (2011) (9)
Relationship of aspirin use with age-related macular degeneration: association or causation?: comment on "The association of aspirin use with age-related macular degeneration". (2013) (9)
Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone? (2011) (9)
On reporting of effect size in randomized clinical trials. (2013) (9)
A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. (2020) (9)
An orwellian discourse on the meaning and measurement of noninferiority. (2007) (9)
Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy? (2015) (8)
Evidence for the Universal Blood Pressure Goal of <130/80 mm Hg Is Strong (2020) (8)
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022) (8)
Should Percutaneous Coronary Intervention Be Considered for Left Main Coronary Artery Disease?: Insights From a Bayesian Reanalysis of the EXCEL Trial. (2020) (7)
How Strong Is the Evidence to Support Blood Pressure Treatment Goal of 130/80 mm Hg? (2018) (6)
Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old. (2015) (6)
Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study. (2003) (6)
Forbidden fruit: on the analysis of recurrent events in randomized clinical trials. (2013) (6)
Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. (2019) (6)
Non-Inferiority Designed Cardiovascular Trials in Highest-Impact Journals: Main Findings, Methodological Quality and Time Trends. (2019) (6)
Gingival recession: Proposal for a new classification (2012) (5)
Intravascular ultrasound tissue characterization: messages from the heart. (2009) (5)
Expert Consensus Document Accf/acr/aha/nasci/saip/scai/scct 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Writing Committee Members Expert Consensus Document Table of Cont (5)
Biomarkers In Periodontal Diagnosis: “What The Future Holds...” (2011) (5)
Evaluating the Evidence for Coronary Computed Tomography Angiography as the Noninvasive Test of Choice for Patients With Stable Chest Pain. (2019) (5)
The 300-Year-Old Health Care Solution—Reply (2009) (5)
1901-121 Profound Inhibition of Arterial Thrombosis by a Novel Nitric Oxide Donor (1995) (4)
A 300-year-old solution to the health care crisis. (2009) (4)
Immunization with a novel human apo B100 related peptide reduces atherosclerosis and inflammation in apo E null mice (2002) (4)
Are Guidelines for Treatment of Hypertension Trustworthy? (2019) (4)
HOW DOES LEFT ATRIAL APPENDAGE OCCLUSION USING THE WATCHMAN DEVICE COMPARE TO DABIGATRAN FOR REDUCING THROMBOEMBOLIC EVENTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (2010) (4)
Local Delivery of an Ultra-short-acting Nitric Oxide- releasing Compound, DMHD/NO, Is Highly Effective in Inhibiting Acute Platelet-Thrombus Formation on Injured Arterial Strips (1997) (4)
Interlink between stress and periodontal disease (2012) (4)
A novel membrane-type matrix metalloproteinase (MT-MMP) is expressed in human atherosclerotic plaques and localized in macrophages and smooth muscle cells (1998) (4)
Expression Tenascin-C in Human Coronary Atherosclerotic Plaque (1998) (3)
Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology (2018) (3)
Current status and future trends in drug-eluting stents. (2007) (3)
Therapeutic Concentrations of Heparin Augment Platelet Activation at the Time of Coronary Angiography (1998) (3)
Improved prospects for IVUS in identifying vulnerable plaques? (2012) (3)
Erratum: Functional improvement precedes structural regression of atherosclerosis (Circulation (1994) 84 (1810-1818)) (1994) (3)
Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. (2020) (3)
Do Women Really Respond Differently to Antiplatelet Therapies?: The Evidence Just Doesn't Add Up. (2017) (3)
Evaluation of postsurgical clinical outcomes with/without removal of pocket epithelium: A split mouth randomized trial (2014) (3)
Abstract 4014: Timing of Benefit with Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Reanalysis of TRITON-TIMI 38 Results (2008) (3)
A Tale of Two Trials: Reconciling Differences in Results by Exploring Heterogeneous Treatment Effects (2017) (3)
By desperate appliance relieved? On the clinical relevance of risk stratification to therapeutic decision-making. (2012) (3)
Homocysteine and Cardiovascular Disease (2008) (2)
Accf/aha Performance Measure Accf/aha New Insights into the Methodology of Performance Measurement a Report of the American College of Cardiology Foundation/american Heart Association Task Force on Performance Measures Writing Committee Members Accf/aha Task Force on Performance Measures (2010) (2)
DOES RIVAROXABAN PROVIDE A CLINICALLY RELEVANT FAVORABLE BENEFIT-RISK PROFILE COMPARED WITH ENOXAPARIN AFTER HIP OR KNEE ARTHROPLASTY? (2010) (2)
Aortic Valve Replacement 2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter (2012) (2)
ROSIGLITAZONE AND CARDIOVASCULAR RISK: NISSEN AND WOLSKI 2010 UPDATED META-ANALYSIS REVISITED (2011) (2)
Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction. (2016) (2)
Abstract 20910: Are Claims of Effectiveness of MitraClip Device Compared with Surgery for Severe Mitral Regurgitation Substantiated by the Evidence? A Critical Look at the EVEREST II Trial. (2010) (2)
Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 (2017) (2)
Should everolimus-eluting stents be preferred in patients with acute and stable coronary syndromes? (2011) (1)
Understanding the merits and drawbacks of noninferiority designs in cardiovascular medicine. (2021) (1)
PREDICTIVE PERFORMANCE OF PLATELET GENOTYPING: A CRITICAL LOOK (2011) (1)
Harold James Charles ("Jeremy") Swan, MD, PhD (2006) (1)
Abstract 4015: Validity of the Combined Efficacy plus Safety Composite Endpoint (Net Clinical Benefit) in TRITON-TIMI 38 (2008) (1)
Have the risks of rosiglitazone been exaggerated? (2008) (1)
On the Credibility of Subgroup Analyses in the COMPLETE Trial. (2020) (1)
superior or equivalent efficacy compared with unfractionated heparin? Low molecular weight heparin in acute coronary syndrome: evidence for (2011) (1)
Abstract 2652: Bivalirudin During Early Invasive Strategy for Acute Coronary Syndromes: Noninferiority in ACUITY Lies in the Eyes of the Beholder (2006) (1)
Abstract 21109: Bayesian Approach to Moderate Implausible Treatment Effects Observed in Trials Stopped Early: Lessons Learnt from JUPITER Trial. (2010) (1)
ASPIRIN THERAPY FOR PRIMARY VERSUS SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: AN UPDATED META-ANALYSIS. (2010) (1)
Inhibitor in Human Monocyte-Derived Macrophages Oxidized Low-Density Lipoprotein Regulates Matrix Metalloproteinase-9 and Its Tissue (1999) (1)
Decompensated Heart Failure and Diuretic Resistance (2006) (1)
Clopidogrel is more effective than aspirin in inhibiting acute stent thrombosis (1996) (1)
797-3 Restoration of Thromboresistance in Injured Aortic Segments by a Novel Nitric Oxide Donor (1995) (0)
Suppression of contrast-mediated platelet activation by a nitric oxide donor, and NO adduct of dimethylhexane-diamine (1996) (0)
Abstract 18940: Efficacy and Safety of Tirofiban for Bridging Therapy in Patients at High-Risk for Stent Thrombosis Undergoing Surgery (2010) (0)
Abstract 4016: Does Prasugrel Provide a Clinically Important Treatment Benefit Compared with Clopidogrel? A Bayesian Analysis of TRITON-TIMI 38 (2008) (0)
The 300-Year-Old Health Care Solution. Authors' reply (2009) (0)
DAPT rules. (2018) (0)
Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials (2020) (0)
Abstract 4546: Will Long-Term Dual Antiplatelet Therapy Prevent Adverse Events Related to Drug-Eluting Stents? Projections Based on a Markov Model (2009) (0)
Dronedarone and Atrial Fibrillation: A Critical Review (2010) (0)
Force on Performance Measures of the American College of Cardiology Foundation/American Heart Association Task ACCF/AHA New Insights Into the Methodology of Performance Measurement : A Report (2013) (0)
Differences in Glucose Levels Between Arms Using Continuous Glucose Monitors (2022) (0)
Transcatheter Aortic-Valve Replacement in Low-Risk Patients. (2019) (0)
Abstract 2987: Percutaneous Coronary Intervention for Management of CAD: Evidence-Based or Enthusiasm-Bound? (2007) (0)
Is apolipoprotein A-IMilano more efficient in promoting cholesterol efflux than wild-type apolipoprotein A-I? (1997) (0)
P omocysteine Hypothesis for therothrombotic Cardiovascular Disease ot Validated (2006) (0)
Erectile Dysfunction and Cardiovascular Disease (2007) (0)
Is homocysteine a relevant cardiovascular risk factor? (2008) (0)
UNIQUE CREEPING ATTACHMENT AFTER AUTOGENOUS GINGIVAL GRAFTING: A C AS E REPORT (2011) (0)
Inhibition of aortic atherosclerosis in apolipoprotein E-deficient mice by recombinant apolipoprotein A-I Milano (1998) (0)
The Incremental Nature of Clinical Research (2017) (0)
GEOGRAPHIC DISPARITY OF TREATMENT EFFECT IN THE PLATO TRIAL: FACT OR ARTIFACT? (2011) (0)
Abstract 345: Non-inferiority Trials With a Primary Surrogate Endpoint: An Increasing Phenotype in Cardiovascular Trials (2020) (0)
Do glycoprotein 2b3a inhibitors reduce mortality? A Bayesian meta-analysis (2002) (0)
Cigarette smoke creates an unstable atherosclerotic plaque phenotype by enhancing vascular oxidative stress, increasing vascular endothelial growth factor expression and producing collagen loss in apo E -/- mice (2002) (0)
In Memoriam, George A. Diamond, MD 1941 to 2015 (2016) (0)
Revascularization for acute myocardial infarction: thrombolytic therapy or angioplasty — still a burning question (1998) (0)
Using the Appropriate Fishing Net for Computed Tomographic Coronary Angiography in Daily Clinical Practice—Reply (2011) (0)
Obligate role of macrophage colony-stimulating factor for the development of neointimal thickening following arterial injury (2003) (0)
Does the evidence support the verdict of high profile clinical trials? A conventional versus Bayesian perspective (2002) (0)
Document on Transcatheter Aortic Valve Replacement (2012) (0)
Invasive treatment is not superior to conservative treatment in patients with non-Q-wave MI. (1998) (0)
Reassessing Patients Over Time : How To Follow Patients on Treatment (2009) (0)
Abstract 4450: Does the Evidence Support Guideline Recommendations for Clopidogrel Pretreatment? (2008) (0)
Abstract 4200: Does Homocysteine Lowering Impact Cardiovascular Outcomes? A Bayesian Meta-Analysis of NORVIT and HOPE-2 Trials (2006) (0)
Variation in use of invasive procedures in acute ischemic syndromes. (1998) (0)
Pursuit of Myocardial Ischemia for Therapeutic Decision-Making in Patients With Diabetes and Stable Ischemic Heart Disease: Reconciling Randomized Controlled Trials and Observational Studies. (2022) (0)
Rosiglitazone and cardiovascular risk. (2007) (0)
Reversal of impaired endothelium-dependent vasodilatation in apolipoprotein E-deficient mice by recombinant apolipoprotein A-IMilano (1998) (0)
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 (2018) (0)
Duty-Bound: Rational Foundations of Clinical Strategies for Prevention of Cardiovascular Events (2011) (0)
Selective inducible nitric oxide synthase inhibitor mercaptoethylguanidine attenuates neointimal formation in injured mice exposed to cigarette smoke (2002) (0)
Cardiovascular Perspectives Cost, Effectiveness, and Cost-Effectiveness (2009) (0)
Effects of Pulmonary Valve Replacement on QRS Duration and Right Ventricular Cavity Size Late After Repair of Right Ventricular Outflow Tract Obstruction (2005) (0)
Atherothrombotic Cardiovascular Events Remains UnprovenResponse to Kaul et al The Role of Platelet Reactivity and Genotype Testing in the Prevention of (2013) (0)
Coronary Computed Tomography Angiography as the Investigation of Choice for Stable Chest Pain-Reply. (2019) (0)
Reduced serum paraoxonase activity is associated with progression of atherosclerosis and new clinical events: Bezafibrate coronary atherosclerosis intervention trial (1996) (0)
Putting It Together (2009) (0)
MODEST ANTIARRHYTHMIC EFFICACY OF DRONEDARONE FOR ATRIAL FIBRILLATION: RESULTS OF A META-ANALYSIS. (2010) (0)
Homocysteine: A Risk Factor for Atherothrombotic Cardiovascular Disease (2006) (0)
The Socket Science of Immediate Implants - Case Report (2014) (0)
Lessons Learnt from Recent Trials in Ischemic Heart Disease (2020) (0)
OUTCOMES OF CONTEMPORARY NON-INFERIORITY VERSUS SUPERIORITY CARDIOVASCULAR TRIALS (2021) (0)
Choice of Optimal Anticoagulant to Support Primary PCI Out With the In the Old* (0)
coronary syndromes Advances in antiplatelet treatment for acute (2010) (0)
Process of care is affected by the type of health insurance. (1998) (0)
Analysis of CCR Expansion Joints (2019) (0)
Simvastatin with or without ezetimibe in familial hypercholesterolemia. (2008) (0)
Abstract 21035: Drug-Eluting Stents in ST Elevation Myocardial Infarction: An Updated Meta-Analysis (2010) (0)
Abstract 3789: Nessun Dorma: Have the Risks of Rosiglitazone been Exaggerated? (2007) (0)
Recombinant Apolipoprotein A-IMilano Protects Against Lysophosphatidylcholine-induced Endothelial Dysfunction (1998) (0)
A Time to Live: Dynamic Changes in Risk as the Basis for Therapeutic Triage (2011) (0)
Abstract 1949: Are Drug-Eluting Stents Really Worth The Money? Disconnect Between Clinical Trials and Clinical Practice Estimates (2006) (0)
Glycoprotein IIb/IIIa inhibitors (2007) (0)
Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement (2023) (0)
Abstract 4558: An Optimal Selective Strategy for Use of Drug-Eluting Stents Based on a Markov Model of Restenosis and Thrombosis (2009) (0)
Use of magnesium for the prevention of thrombosis in-stent and complications after vascular stent delivery with internal arterioplastik (2002) (0)
Erratum to: The JUPITER Trial: Myth or Reality? (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sanjay Kaul?

Sanjay Kaul is affiliated with the following schools:

Sanjay Kaul's Academic­Influence.com Rankings

Sanjay Kaul's Degrees

Similar Degrees You Can Earn

Why Is Sanjay Kaul Influential?

Sanjay Kaul's Published Works

Published Works

What Schools Are Affiliated With Sanjay Kaul?

Sanjay Kaul's AcademicInfluence.com Rankings